Michigan Team Implants First-In-Human Paradromics Wireless BCI

Surgeons at University of Michigan have implanted a Paradromics wireless brain-computer interface in a human patient for the first time, the health system announced. The device is designed to restore communication for people who have lost the ability to speak.

The implantation marks the company's transition from preclinical development into first-in-human evaluation. Paradromics, an Austin-based neurotechnology company, has built its platform around a fully implantable, wireless neural interface intended to record high-channel-count brain activity and translate it into a communication output.

Michigan Medicine has not disclosed the identity of the first participant, the date of the procedure, or the underlying diagnosis that caused the patient's loss of communication. First-in-human trials of this type typically enroll individuals with severe paralysis from conditions such as amyotrophic lateral sclerosis, brainstem stroke, or spinal cord injury, but the institution has not confirmed which population this trial targets.

The device is investigational. It does not carry FDA clearance or approval, and the implantation took place as part of an early-stage clinical evaluation rather than routine clinical care. Readers in epilepsy monitoring units and clinical neurophysiology labs should treat this as a research milestone, not a device they will encounter on a ward round.

What a wireless, fully implanted BCI means for the reading room

Most clinical neurophysiologists know brain-computer interface research largely through intracranial electrocorticography (ECoG) arrays and depth electrodes borrowed from epilepsy presurgical monitoring. Those systems are tethered: patients connect to amplifiers through percutaneous leads, which limits recording duration, raises infection risk over long implants, and confines BCI demonstrations to laboratory sessions.

A fully wireless, implantable interface addresses those constraints directly. No percutaneous connectors means a lower long-term infection burden, and chronic implanted recording means the communication system can be tested in the patient's daily environment rather than only in a controlled lab. The trade-off, familiar to anyone who has worked with implanted devices, is that everything — amplification, digitization, power, and telemetry — must fit inside the implant package and survive years of in-vivo operation.

Michigan Medicine and Paradromics have not yet published the recording modality details that clinical readers will want: electrode type, channel count, cortical target, sampling rate, or signal bandwidth. The company has previously described its platform as a high-channel-count cortical interface, but the specific configuration implanted in this first patient has not been confirmed in the announcement.

The communication-restoration goal

The clinical target is communication — decoding intended speech or text output from cortical signals. This is a crowded and fast-moving field. Recent years have brought demonstrations of speech decoding from intracortical microelectrode arrays and ECoG grids in patients with amyotrophic lateral sclerosis and aphasia, with several groups reporting vocabulary sizes in the tens of thousands of words and decoding speeds approaching conversational rates.

What separates this announcement from those studies is the device class: a wireless, fully implanted commercial system entering first-in-human testing, rather than a wired research array in an academic lab. If the Paradromics device proves durable and its decoding performance holds in ambulatory, real-world settings, it would represent a step toward BCI communication as a deployable therapy rather than an experimental demonstration.

That step remains unproven. First-in-human implantation establishes safety and feasibility in a single participant. It does not establish decoding accuracy, durability across months or years, or benefit in a defined patient population. Those questions fall to the subsequent phases of the clinical program, which Michigan Medicine has not yet detailed — no enrollment targets, study sites beyond Michigan, or primary endpoints have been announced.

What to watch next

For clinical neurophysiologists, the items that will define whether this milestone matters in practice are concrete: the confirmed electrode configuration and cortical coverage; the first published signal-quality data from the implanted device; the decoding results reported against an established benchmark such as words per minute or character error rate; and safety data over the first year of implantation.

Michigan Medicine says the program is designed to move toward restoring communication for patients who cannot speak, and the surgical team has completed the first implant. The field will now be watching for the first functional results from this patient — and for word on when, and how many, additional participants will follow.